Which mineralocorticoid receptor antagonist is recommended as first‑line therapy for chronic kidney disease, considering eGFR and serum potassium thresholds?

Mineralocorticoid Receptor Antagonist Selection for Chronic Kidney Disease

Nonsteroidal MRAs—specifically finerenone—are the recommended first-line mineralocorticoid receptor antagonist for adults with type 2 diabetes, CKD, eGFR >25 ml/min/1.73 m², normal serum potassium (≤4.8 mmol/L), and persistent albuminuria (>30 mg/g) despite maximum tolerated RAS inhibitor therapy. 1

Patient Selection Criteria

Ideal candidates for nonsteroidal MRA therapy must meet all of the following thresholds 1:

• Type 2 diabetes with chronic kidney disease
• eGFR >25 ml/min/1.73 m² at initiation
• Serum potassium ≤4.8 mmol/L consistently (not just a single measurement)
• Albuminuria >30 mg/g (>3 mg/mmol) persisting despite maximum tolerated RAS inhibitor dose
• High risk of CKD progression demonstrated by persistent albuminuria despite standard-of-care therapies

The KDIGO 2024 guideline emphasizes that nonsteroidal MRAs are most appropriate for patients at high cardiovascular and kidney risk, as evidenced by albuminuria that remains elevated despite optimized RASi therapy 1. This represents residual risk that warrants additional intervention.

Finerenone Dosing Algorithm

Initiation dosing is determined by baseline eGFR and potassium 1:

Baseline K⁺	eGFR 25–59 ml/min/1.73 m²	eGFR ≥60 ml/min/1.73 m²
≤4.8 mmol/L	Start 10 mg daily	Start 20 mg daily
4.9–5.5 mmol/L	Do not initiate; address hyperkalemia first	Do not initiate; address hyperkalemia first
>5.5 mmol/L	Contraindicated	Contraindicated

Dose titration after 4 weeks 1:

• If K⁺ remains ≤4.8 mmol/L and patient started on 10 mg daily → increase to 20 mg daily
• If K⁺ 4.9–5.5 mmol/L → continue current dose, monitor K⁺ every 4 months
• If K⁺ >5.5 mmol/L → hold finerenone, adjust diet/medications, recheck K⁺, consider reinitiation when K⁺ ≤5.0 mmol/L

Potassium Monitoring Protocol

Critical monitoring intervals 1:

• 1 month after initiation or dose increase
• Every 4 months during maintenance therapy
• Within 1 week after any intercurrent illness, medication change, or dietary modification that could affect potassium

The guideline explicitly states to select patients with "consistently normal serum potassium concentration"—not just a single normal value—before starting therapy 1. This reduces hyperkalemia risk substantially.

Nonsteroidal vs. Steroidal MRAs

Nonsteroidal MRAs (finerenone) are strongly preferred over steroidal MRAs (spironolactone, eplerenone) for CKD management because 1, 2, 3, 4, 5:

• Lower hyperkalemia risk: Finerenone causes less potassium elevation than spironolactone or eplerenone at equivalent efficacy
• Proven kidney and cardiovascular outcomes: The FIDELIO-DKD trial demonstrated that finerenone reduces composite kidney outcomes (kidney failure, sustained eGFR decline ≥40%, renal death) and cardiovascular events (CV death, nonfatal MI, nonfatal stroke, hospitalization for heart failure) compared to placebo 2, 3
• No sex hormone effects: Unlike spironolactone, finerenone does not cause gynecomastia or breast disorders 5
• Better tolerability: Fewer discontinuations due to adverse effects compared to steroidal MRAs 2, 4

Steroidal MRAs may still be used for specific indications—heart failure with reduced ejection fraction, primary hyperaldosteronism, or refractory hypertension—but carry higher hyperkalemia risk and reversible GFR decline, particularly when eGFR is low 1. The guideline explicitly notes these agents "may cause hyperkalemia or a reversible decline in glomerular filtration, particularly among people with a low GFR" 1.

Combination with SGLT2 Inhibitors and RAS Inhibitors

Nonsteroidal MRAs can and should be added to existing RASi and SGLT2i therapy in appropriate patients 1. The guideline states: "A nonsteroidal MRA may be added to a RASi and an SGLT2i for treatment of T2D and CKD in adults" 1.

This triple therapy approach targets complementary pathways:

• RASi: Reduces intraglomerular pressure and proteinuria
• SGLT2i: Reduces hyperfiltration, provides metabolic benefits, reduces cardiovascular events
• Nonsteroidal MRA: Blocks aldosterone-mediated inflammation and fibrosis in kidney and heart

Recent meta-analysis data show that MRA plus SGLT2i reduces albuminuria by an additional 33.6% compared to SGLT2i alone, with systolic blood pressure reduction of 6.1 mm Hg 6. The potassium increase with combination therapy (+0.23 mmol/L) is predictable and manageable 6.

Common Pitfalls and How to Avoid Them

Do not withhold finerenone solely because eGFR declines after initiation 1. A small, reversible eGFR decrease is expected and does not indicate treatment failure or harm. Continue therapy unless eGFR falls to ≤25 ml/min/1.73 m² or potassium becomes unmanageable.

Do not initiate finerenone if baseline potassium is >4.8 mmol/L 1. First optimize potassium through dietary counseling, diuretic adjustment, or potassium binders. Recheck potassium after interventions and initiate finerenone only when consistently ≤4.8 mmol/L.

Do not use steroidal MRAs (spironolactone, eplerenone) as first-line for diabetic CKD unless finerenone is unavailable or contraindicated 1, 2. The evidence base and safety profile favor nonsteroidal agents for this indication.

Do not forget to check potassium at 1 month 1. This is the highest-risk period for hyperkalemia. Missing this check can lead to dangerous potassium elevations going undetected.

Do not automatically discontinue finerenone if potassium rises to 4.9–5.5 mmol/L 1. Continue the current dose and monitor every 4 months. Only hold therapy if K⁺ exceeds 5.5 mmol/L.

Evidence Quality and Strength

The KDIGO 2024 recommendation for nonsteroidal MRAs in diabetic CKD is Grade 2A (suggest, moderate-quality evidence) 1. This reflects:

• Strong efficacy data from the FIDELIO-DKD trial (>5,000 patients) showing kidney and cardiovascular benefits 2, 3
• Consistent safety profile across multiple trials with predictable and manageable hyperkalemia 2, 4, 5
• Mechanistic rationale supported by preclinical and clinical studies demonstrating that MR blockade reduces inflammation, fibrosis, and albuminuria 3

The recommendation is a "suggest" rather than "recommend" primarily because the absolute risk reduction varies by baseline risk, and patient preferences regarding pill burden and monitoring requirements should be considered 1.

When Nonsteroidal MRAs Are Not Appropriate

Absolute contraindications 1:

• eGFR ≤25 ml/min/1.73 m² at baseline
• Serum potassium >5.5 mmol/L despite optimization
• Inability to adhere to potassium monitoring schedule

Relative contraindications requiring careful consideration:

• Recurrent hyperkalemia episodes despite dietary modification and potassium binders
• Concurrent use of multiple medications that raise potassium (NSAIDs, potassium-sparing diuretics, trimethoprim)
• Advanced age with multiple comorbidities limiting life expectancy to <1 year

In these scenarios, the risk-benefit balance may not favor MRA therapy, and focus should remain on optimizing RASi and SGLT2i therapy 1.